Stonebridge Capital Management’s Merrimack Pharmaceuticals, Inc. MACK Stock Holding History

Stonebridge Capital Management’s Portfolio MACK Stock Details MACK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-43,379	Closed	-$182K	–	146
2018 Q3	$182K	Buy	43,379 +17,038	+65%	+$71.8K	0.06%	125
2018 Q2	$106K	Buy	26,341 +381	+1%	+$2.53K	0.04%	128
2018 Q1	$177K	Buy	25,960 +2,383	+10%	+$19.7K	0.06%	122
2017 Q4	$200K	Buy	+23,577	New	+$220K	0.07%	126
2017 Q3	–	Sell	-10,257	Closed	-$100K	–	145
2017 Q2	$100K	Buy	10,257 +5,615	+121%	+$115K	0.04%	134
2017 Q1	$112K	Buy	+4,642	New	+$116K	0.05%	120

Other funds holding MACK

Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return

22NW LP Seattle, Washington $146M AUM 29.83% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Sepio Capital Salt Lake City, Utah $1.84B AUM 18.57% 1-Year Est. Return

TCIM

TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return

Clearline Capital New York $1.93B AUM 38.13% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

WIM

Wittenberg Investment Management Carlisle, Massachusetts $269M AUM 28.17% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Stonebridge Capital Management's MACK Position: Q4 2018 in Review

Stonebridge Capital Management sold out of Merrimack Pharmaceuticals, Inc. (MACK) in Q4 2018, closing a stake of 43,379 shares — an estimated $182K sold.

Stonebridge Capital Management first reported a position in MACK in Q1 2017 and held it in 6 quarters. The position peaked at $200K in Q4 2017. 56 funds tracked by Wall St. Rank hold MACK as of Q4 2018.

Stonebridge Capital Management reported no remaining Merrimack Pharmaceuticals, Inc. position as of Q4 2018 after selling out during the quarter.
Stonebridge Capital Management sold 43,379 Merrimack Pharmaceuticals, Inc. shares in Q4 2018, an estimated $182K.
Stonebridge Capital Management first reported a position in Merrimack Pharmaceuticals, Inc. in Q1 2017 and held it in 6 quarters.
Stonebridge Capital Management's Merrimack Pharmaceuticals, Inc. position peaked at $200K in Q4 2017.
56 funds tracked by Wall St. Rank held Merrimack Pharmaceuticals, Inc. as of Q4 2018.

Based on Stonebridge Capital Management's 13F filing for Q4 2018, filed 24 Jan 2019.